Targeting breast cancer-associated fibroblasts to improve anti-cancer therapy

Breast

Volumn 24, Issue 5, 2015, Pages 532-538

  Slany, Astrid ^a   Bileck, Andrea ^a   Muqaku, Besnik ^a   Gerner, Christopher ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Breast cancer; Cancer associated fibroblasts; Drug evaluation; Mass spectrometry; Proteome profiling; Targeted proteomics

Indexed keywords

ARTICLE; BREAST CANCER; CANCER ASSOCIATED FIBROBLAST; CANCER THERAPY; CELL INTERACTION; DRUG SCREENING; DRUG TARGETING; FIBROBLAST; HUMAN; PRIORITY JOURNAL; PROTEOMICS; STROMA CELL; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; BIOLOGICAL MODEL; BREAST NEOPLASMS; DRUG DEVELOPMENT; DRUG EFFECTS; FEMALE; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY;

BREAST NEOPLASMS; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FIBROBLASTS; HUMANS; MASS SPECTROMETRY; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; PROTEOMICS; RESEARCH DESIGN; TUMOR MICROENVIRONMENT;

EID: 84952637138     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2015.06.009     Document Type: Article

References (33)

1. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics. CA Cancer J Clin 2012, 2015.
2. Conklin M.W., Keely P.J. Why the stroma matters in breast cancer: insights into breast cancer patient outcomes through the examination of stromal biomarkers. Cell Adh Migr 2012, 6(3):249-260.
3. Obenauf A.C., Zou Y., Ji A.L., Vanharanta S., Shu W., Shi H., et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 2015.
4. Karagiannis G.S., Poutahidis T., Erdman S.E., Kirsch R., Riddell R.H., Diamandis E.P. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol Cancer Res 2012, 10(11):1403-1418.
5. Reisfeld R.A. The tumor microenvironment: a target for combination therapy of breast cancer. Crit Rev Oncog 2013, 18(1-2):115-133.
6. Criscitiello C., Esposito A., Curigliano G. Tumor-stroma crosstalk: targeting stroma in breast cancer. Curr Opin Oncol 2014, 26(6):551-555.
7. Marsh T., Pietras K., McAllister S.S. Fibroblasts as architects of cancer pathogenesis. Biochim Biophys Acta 2013, 1832(7):1070-1078.
8. Slany A., Haudek-Prinz V., Zwickl H., Stattner S., Grasl-Kraupp B., Gerner C. Myofibroblasts are important contributors to human hepatocellular carcinoma: evidence for tumor promotion by proteome profiling. Electrophoresis 2013, 34(24):3315-3325.
9. Slany A., Haudek-Prinz V., Meshcheryakova A., Bileck A., Lamm W., Zielinski C., et al. Extracellular matrix remodeling by bone marrow fibroblast-like cells correlates with disease progression in multiple myeloma. J Proteome Res 2014, 13(2):844-854.
10. Groessl M., Slany A., Bileck A., Gloessmann K., Kreutz D., Jaeger W., et al. Proteome profiling of breast cancer biopsies reveals a wound healing signature of cancer-associated fibroblasts. J Proteome Res 2014, 13(11):4773-4782.
11. Bissell M.J., Hines W.C. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011, 17(3):320-329.
12. Dittrich J., Becker S., Hecht M., Ceglarek U. Sample preparation strategies for targeted proteomics via proteotypic peptides in human blood using liquid chromatography tandem mass spectrometry. Proteomics Clin Appl 2015, 9(1-2):5-16.
13. Jeong K., Kim S., Bandeira N. False discovery rates in spectral identification. BMC Bioinforma 2012, 13(Suppl. 16).
14. Wilhelm M., Schlegl J., Hahne H., Moghaddas Gholami A., Lieberenz M., Savitski M.M., et al. Mass-spectrometry-based draft of the human proteome. Nature 2014, 509(7502):582-587.
15. Slany A., Meshcheryakova A., Beer A., Ankersmit H., Paulitschke V., Gerner C. Plasticity of fibroblasts demonstrated by tissue-specific and function-related proteome profiling. Clin Proteomics 2014, 11(1):41.
16. Paulitschke V., Berger W., Paulitschke P., Hofstaetter E., Knapp B., Dingelmaier-Hovorka R., et al. Vemurafenib resistance signature by proteome analysis offers new strategies and rational therapeutic concepts. Mol Cancer Ther 2015.
17. Paulitschke V., Haudek-Prinz V., Griss J., Berger W., Mohr T., Pehamberger H., et al. Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells. J Proteome Res 2013, 12(7):3264-3276.
18. Nagaraj N., Kulak N.A., Cox J., Neuhauser N., Mayr K., Hoerning O., et al. System-wide perturbation analysis with nearly complete coverage of the yeast proteome by single-shot ultra HPLC runs on a bench top orbitrap. Mol Cell Proteomics 2012, 11(3). M111 013722.
19. Vidal M., Chan D.W., Gerstein M., Mann M., Omenn G.S., Tagle D., et al. The human proteome - a scientific opportunity for transforming diagnostics, therapeutics, and healthcare. Clin Proteomics 2012, 9(1):6.
20. Gillet L.C., Navarro P., Tate S., Rost H., Selevsek N., Reiter L., et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics 2012, 11(6). O111 016717.
21. Bileck A., Kreutz D., Muqaku B., Slany A., Gerner C. Comprehensive assessment of proteins regulated by dexamethasone reveals novel effects in primary human peripheral blood mononuclear cells. J Proteome Res 2014, 13(12):5989-6000.
22. Abbatiello S.E., Schilling B., Mani D.R., Zimmerman L.J., Hall S.C., MacLean B., et al. Large-scale inter-laboratory study to develop, analytically validate and apply highly multiplexed, quantitative peptide assays to measure cancer-relevant proteins in plasma. Mol Cell Proteomics 2015.
23. Percy A.J., Chambers A.G., Yang J., Hardie D.B., Borchers C.H. Advances in multiplexed MRM-based protein biomarker quantitation toward clinical utility. Biochim Biophys Acta 2014, 1844(5):917-926.
24. Schamberger C.J., Gerner C., Cerni C. bFGF rescues 423-cells from serum starvation-induced apoptosis downstream of activated caspase-3. FEBS Lett 2004, 573(1-3):19-25.
25. Schamberger C.J., Gerner C., Cerni C. Caspase-9 plays a marginal role in serum starvation-induced apoptosis. Exp Cell Res 2005, 302(1):115-128.
26. Vejda S., Posovszky C., Zelzer S., Peter B., Bayer E., Gelbmann D., et al. Plasma from cancer patients featuring a characteristic protein composition mediates protection against apoptosis. Mol Cell Proteomics 2002, 1(5):387-393.
27. Mayer E.L. Targeting breast cancer with CDK inhibitors. Curr Oncol Rep 2015, 17(5):443.
28. Grassadonia A., Caporale M., Tinari N., Zilli M., DeTursi M., Gamucci T., et al. Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: a systematic review. J Cancer 2015, 6(6):575-582.
29. Wang X.G., Meng Q., Qi F.M., Yang Q.F. Blocking TGF-beta inhibits breast cancer cell invasiveness via ERK/S100A4 signal. Eur Rev Med Pharmacol Sci 2014, 18(24):3844-3853.
30. Lisanti M.P., Martinez-Outschoorn U.E., Sotgia F. Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and "fibroblast addiction" are new therapeutic targets for drug discovery. Cell Cycle 2013, 12(17):2723-2732.
31. Leone A., Di Gennaro E., Bruzzese F., Avallone A., Budillon A. New perspective for an old antidiabetic drug: metformin as anticancer agent. Cancer Treat Res 2014, 159:355-376.
32. Bandyopadhyay D. Farmer to pharmacist: curcumin as an anti-invasive and antimetastatic agent for the treatment of cancer. Front Chem 2014, 2:113.
33. Page D.B., Naidoo J., McArthur H.L. Emerging immunotherapy strategies in breast cancer. Immunotherapy 2014, 6(2):195-209.